Slide 1: Q2 2023 results
Q2 2023 results Ahead of outlook for Q2 2023 net sales and adjusted EPS August 9, 2023
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, deemed to be forward looking statements within the meaning of Section 27A of the U.S.
Slide 3: Q2 2023: Non-COVID sales driven by resilient consumable business
Q2 2023: Non-COVID sales driven by resilient consumable business Net $497 million CER(1) Achieved Q2 outlook for net sales and adjusted EPS sales +9% CER non-COVID • +9% CER growth in non-COVID product groups (+10% CER in H1 2023) vs outlook of ≥ $490 m CER Pillars of Growth making good progress Adj
Slide 4: Q2 2023: +9% CER growth in non-COVID product groups
Q2 2023: +9% CER growth in non-COVID product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) -4% -4% (-3.5% CER) (-3.5% CER) $516 $516 $495 $495 Non-COVID product groups 178 165 Sample technologies -7% CER +9% CER 423 457 157 177 Diagno
Slide 5: Q2 2023: Solid non-COVID CER growth in all regions
Q2 2023: Solid non-COVID CER growth in all regions Americas • U.S. leads with strong QuantiFERON and QIAcuity EMEA digital PCR sales $151 m • Strong non-COVID sales in Brazil and Mexico Americas +10% CER non-COVID $263 m Europe / Middle East / Africa • Good transition underway of +9% CER non-COVID Q
Slide 6: Q2 2023: Investing in the business to deliver long-term growth
Q2 2023: Investing in the business to deliver long-term growth Adj. operating income Adj. diluted EPS Operating cash flow (In $ millions) (In $ per share) (In $ millions) ~10% of sales invested into R&D in H1 2023 $379 $146 $136 $0.51 $183 $0.51 ($0.52 CER) 28.4% 27.4% Q2 2022 Q2 2023 Q2 2022 Q2 202
Slide 7: Outlook: Q3 and FY 2023
Outlook: Q3 and FY 2023 Q3 2023 outlook Updated FY 2023 outlook (As of August 8, 2023) Net sales ≥ $465 million CER ≥ $1.97 billion CER Anticipated currency impact Up to ~1 percentage point benefit Neutral FX impact (Prior ≥ $2.05 billion CER) ≥ $2.07 CER Adjusted diluted EPS ≥ $0.48 CER Neutral FX
Slide 8: FY 2023 sales perspectives
FY 2023 sales perspectives Updated 2023 outlook vs. 2022 results Updated 2023 outlook vs. 2019 results (2023 in $ millions at CER, 2022 in $ millions actual rates) (2023 in $ millions at CER, 2019 in $ millions at actual rates, CAGRs calculated on FX-neutral basis) 2,142 ~-65% CER ~1,970 CER ~1,970
Slide 9: Leadership change in Life Sciences Business Area
Leadership change in Life Sciences Business Area Thomas Schweins Nitin Sood • After nearly 20 years with QIAGEN, has decided • Joins October 1 as Senior Vice President Head to step down from his current role and support of Life Sciences Business Area and member of transition to his successor until h
Slide 10: Summary
Summary Resilient business delivering solid results Q2 2023: Above outlook with net $497 million CER net sales, $0.52 CER adj. diluted EPS +9% CER sales in non-COVID portfolio with above-market growth Driven by strong growth above market from heavily consumables portfolio Balancing costs while inves
Slide 11: Appendix
Appendix
Slide 12: Q3 and FY 2023: Outlook and assumptions
Q3 and FY 2023: Outlook and assumptions (As of August 8, 2023) Q3 2023 outlook Updated FY 2023 outlook ~$1.97 billion CER Net sales > $465 million CER (Prior > $2.05 billion CER) Anticipated currency impact(1) Up to +~1 ppt Neutral FX impact ~$2.07 CER Adjusted diluted EPS(2) > $0.48 CER (Prior > $2
Slide 13: Q2 2023: Consolidated Statements of Income (unaudited)
Q2 2023: Consolidated Statements of Income (unaudited) Three months ended Three months ended (In $ thousands, except share data) June 30, 2023 June 30, 2022 Net sales 494,857 515,512 Cost of sales: Cost of sales 166,637 169,381 Acquisition-related intangible amortization 16,068 15,113 Total cost of
Slide 14: H1 2023: Consolidated Statements of Income (unaudited)
H1 2023: Consolidated Statements of Income (unaudited) Six months ended Six months ended (In $ thousands, except share data) June 30, 2023 June 30, 2022 Net sales 980,255 1,143,903 Cost of sales: Cost of sales 328,543 367,499 Acquisition-related intangible amortization 32,084 30,416 Total cost of sa
Slide 15: 2023: Quarterly sales by product group
2023: Quarterly sales by product group (In $ millions at actual rates / Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 173 -35% 32% 165 -7% -7% 338 -24% -22% Diagnostic solutions(1) 1
Slide 16: 2023: Sales by non-COVID and COVID-19 product groups
2023: Sales by non-COVID and COVID-19 product groups (In $ millions at actual rates / Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 434 8% 12% 457 8% 9% 891 8% 10% COVID-19 prod
Slide 17: 2023: Quarterly sales by product type, customer class and region
2023: Quarterly sales by product type, customer class and region (In $ millions at actual rates / Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 431 -23% -21% 434 -4%
Slide 18: Q2 and H1 2023: Reconciliation to adjusted results (unaudited)
Q2 and H1 2023: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pretax Income Tax Net Diluted sales profit income income tax rate income EPS Second quarter 2023 Reported results 494.9 312.1 105.4 102.3 (21.5) 21% 80.8 0.35 Adjustments Business integrati
Slide 19: Q2 and H1 2023: Footnotes for reconciliation to adjusted results
Q2 and H1 2023: Footnotes for reconciliation to adjusted results (unaudited) a) Results for 2023 include costs for acquisition projects, including the acquisition of Verogen Inc. completed on January 4, 2023. Results for 2022 include acquisition projects including continued integration activities at
Slide 20: 2023: Quarterly income statement summary
2023: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 Net sales 485.4 494.9 980.3 Net sales (CER) 501.6 497.4 999.0 Gross profit 307.5 312.1 619.6 Gross profit margin 63.3% 63.1% 63.2% Adjusted gross profit 326
Slide 21: Consolidated Balance Sheets
Consolidated Balance Sheets June 30, December 31, June 30, December 31, (In $ thousands, except par value) 2023 2022 (In $ thousands, except par value) 2023 2022 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 609,549 730,669 Current portion of long-term debt 500,149
Slide 22: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Six months ended June 30, June 30, Six months ended June 30, June 30, (In $ thousands) 2023 2022 (In $ thousands) 2023 2022 Cash flows from operating activities: Cash flows from financing activities: Net income 165,821 251,973 Proceeds from issuance
Slide 23: Q2 and H1 2023: Currency impact
Q2 and H1 2023: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q2 2023 0 U.S. dollar 263.8 263.8 53% 0.0 Euro 100.8 98.6 20% -2.2 British pound 20.4 20.5 4% 0.1 Japanese yen 9.7 10.3 2% 0.6 Other currencies 100.1 104.2
Slide 24: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Q3 2023 results October 2023 Phone: +49 2103 29 11457 Mobile: +49 152 018 11457 Q4 and FY 2023 results February 2024 E-mail: phoebe.loh@qiagen.com Share information Alexandra Koenig Coordinator NYSE: QGEN Investor Relations